# Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds

> **NCT03436160** · EARLY_PHASE1 · COMPLETED · sponsor: **U.S. Army Medical Research and Development Command** · enrollment: 18 (actual)

## Conditions studied

- Malaria

## Interventions

- **DRUG:** WR826647
- **DRUG:** WR909388
- **DRUG:** WR909390

## Key facts

- **NCT ID:** NCT03436160
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-10
- **Primary completion:** 2018-11-03
- **Final completion:** 2018-11-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-03-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03436160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03436160, "Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03436160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*